These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 16730267)

  • 1. Checkpoint blockade in cancer immunotherapy.
    Korman AJ; Peggs KS; Allison JP
    Adv Immunol; 2006; 90():297-339. PubMed ID: 16730267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint therapy for non-small-cell lung cancer: an update.
    Xia B; Herbst RS
    Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nobel goes to immune checkpoint-Innovative cancer treatment by immunotherapy.
    Li J; Dong C
    Sci China Life Sci; 2018 Nov; 61(11):1445-1450. PubMed ID: 30377902
    [No Abstract]   [Full Text] [Related]  

  • 5. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques.
    Keler T; Halk E; Vitale L; O'Neill T; Blanset D; Lee S; Srinivasan M; Graziano RF; Davis T; Lonberg N; Korman A
    J Immunol; 2003 Dec; 171(11):6251-9. PubMed ID: 14634142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTLA-4: negative regulator of the immune response and a target for cancer therapy.
    Keilholz U
    J Immunother; 2008 Jun; 31(5):431-9. PubMed ID: 18463542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTLA-4 blockade: autoimmunity as treatment.
    Kapadia D; Fong L
    J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
    Weber J
    Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future directions in tumor immunotherapy: CTLA4 blockade.
    Gulley JL; Dahut WL
    Nat Clin Pract Oncol; 2007 Mar; 4(3):136-7. PubMed ID: 17327854
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.
    Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M
    Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma.
    Tykodi SS
    Immunotherapy; 2013 Jun; 5(6):607-19. PubMed ID: 23725284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current developments with peptide-based human tumor vaccines.
    Khazaie K; Bonertz A; Beckhove P
    Curr Opin Oncol; 2009 Nov; 21(6):524-30. PubMed ID: 19770763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.
    Mougel A; Terme M; Tanchot C
    Front Immunol; 2019; 10():467. PubMed ID: 30923527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
    Pico de Coaña Y; Choudhury A; Kiessling R
    Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The blockade of immune checkpoints in cancer immunotherapy.
    Pardoll DM
    Nat Rev Cancer; 2012 Mar; 12(4):252-64. PubMed ID: 22437870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity.
    Vogel I; Kasran A; Cremer J; Kim YJ; Boon L; Van Gool SW; Ceuppens JL
    Eur J Immunol; 2015 Jun; 45(6):1832-41. PubMed ID: 25727069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.